Eva Compérat, MD, PhD, Medical University of Vienna, Vienna, Austria, provides an overview of what is expected to happen in innovation and care for prostate cancer in the next 12 months from the pathologist’s perspective, including with biomarker testing and artificial intelligence (AI). This interview took place at the EAU congress in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.